ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $56.63 and traded as low as $51.80. ProShares Ultra Nasdaq Biotechnology shares last traded at $52.14, with a volume of 3,584 shares traded.
ProShares Ultra Nasdaq Biotechnology Stock Down 1.1 %
The company's 50 day simple moving average is $56.47 and its 200 day simple moving average is $61.29.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
The firm also recently announced a dividend, which was paid on Tuesday, December 31st. Investors of record on Monday, December 23rd were paid a $0.3964 dividend. This is a positive change from ProShares Ultra Nasdaq Biotechnology's previous dividend of $0.15. The ex-dividend date was Monday, December 23rd.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in ProShares Ultra Nasdaq Biotechnology stock. Jane Street Group LLC boosted its position in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Free Report) by 8.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,803 shares of the exchange traded fund's stock after acquiring an additional 374 shares during the quarter. Jane Street Group LLC owned 0.35% of ProShares Ultra Nasdaq Biotechnology worth $306,000 as of its most recent filing with the Securities and Exchange Commission.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Recommended Stories
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
